Subject: Semax, Selank & SSRIs: What the Research Says About Combining Them
From: Derek from Peptide Price <[email-masked]>
To: [email-masked]
Date: Mon, 23 Mar 2026 16:50:25 +0000
List-Id: <derekpruski.substack.com>

View this post on the web at https://derekpruski.substack.com/p/semax-selank-and-ssris-what-the-research

For research and educational purposes only. Not for human consumption. Not medical advice.
I get asked about SSRIs constantly. Every nootropic peptide post, every Q&A, every comment section. “Can I use this on an SSRI?” “Will this interact with my antidepressant?” “Is it safe to combine?”
It’s the most common question in the nootropic space — and it deserves a real answer, not a blanket “talk to your doctor” and nothing else.
So let’s start here, with the two nootropic peptides I get this question about the most: Semax and Selank. They’re the most studied nootropic peptides in this category, they both interact with the serotonin system in some capacity, and they’re genuinely different from each other in ways that matter for this conversation.
This is not medical advice. Do not make changes to any prescription medication without talking to your prescribing physician. That part is non-negotiable — but it doesn’t mean we can’t look at the mechanisms and have an informed conversation about what the research actually shows.
What These Peptides Actually Do
Before getting into interactions, a quick recap on mechanisms.
Semax is derived from a fragment of ACTH — a hormone your brain produces naturally as part of the stress response. Researchers modified that fragment to remove the hormonal activity and amplify the neurological effects. The result is a peptide that primarily works by upregulating BDNF — brain-derived neurotrophic factor. BDNF is essentially fertilizer for your neurons. It supports their growth and survival, strengthens synaptic connections, and plays a central role in learning, memory, and cognitive resilience. Beyond BDNF, Semax also modulates dopaminergic and serotonergic signaling — influencing how dopamine and serotonin are released and utilized in key brain regions. Research interest centers on cognitive enhancement, neuroprotection, and focus.
Selank is derived from tuftsin, an immune peptide the body produces naturally. Its primary mechanism is GABAergic modulation — it influences the GABA system, which is the brain’s main inhibitory (calming) network. It also affects enkephalins, which are endogenous opioid peptides involved in mood and stress regulation. And like Semax, Selank has a documented interaction with serotonin metabolism — research has found it can slow the enzymatic breakdown of serotonin in certain brain regions, effectively increasing serotonin availability. Research interest centers on anxiety reduction, stress resilience, and cognitive clarity under pressure.
The short version: Semax skews stimulating and cognitively activating, driven mainly by BDNF and dopamine. Selank skews calming and anxiolytic, driven mainly by GABA and serotonin preservation.
How SSRIs Work
SSRIs — selective serotonin reuptake inhibitors — block the reuptake of serotonin in the synaptic cleft. When a neuron fires and releases serotonin, that serotonin would normally get pulled back into the sending neuron relatively quickly. SSRIs block that transporter, so serotonin lingers in the synapse longer, increasing serotonergic signaling over time. Common examples: sertraline (Zoloft), fluoxetine (Prozac), escitalopram (Lexapro), paroxetine (Paxil).
The concern is reasonable — if both peptides interact with serotonin in some way, and SSRIs are directly targeting that same system, is there potential for amplification, interference, or something more serious?
Yes, there’s theoretical overlap. But the nature of that overlap is more nuanced than most people assume.
Where the Overlap Actually Exists
Selank carries the more direct serotonin overlap. Research has found it reduces the activity of enzymes responsible for breaking down serotonin — effectively increasing serotonin availability through a degradation pathway. This is mechanistically distinct from what SSRIs do (which act on the reuptake transporter), but the net direction is the same: both push toward elevated serotonergic activity.
The concern this raises is serotonin syndrome — a condition caused by excessive serotonergic stimulation, ranging from mild (restlessness, elevated heart rate, sweating) to severe. That said, serotonin syndrome most commonly results from combining multiple agents that each directly and potently target the serotonin system. Selank’s effect on serotonin is comparatively mild and indirect — it’s not hitting the reuptake transporter the way an SSRI does. There is no published research documenting serotonin syndrome from Selank combined with SSRIs, and no known case reports in the literature.
The combination shouldn’t be dismissed outright — but it also shouldn’t be treated as equivalent to stacking two direct serotonergic drugs. The more practical flag is this: someone on an SSRI for clinical anxiety or depression is already pharmacologically treating a condition that Selank is being researched to address. Layering the two without physician awareness is not a reasonable approach.
Semax carries less direct serotonin overlap. Research shows Semax modulates serotonin release in a region-specific way, but its primary mechanism is BDNF — and BDNF has a well-documented relationship with serotonergic systems in the antidepressant literature. BDNF upregulation is actually one of the proposed long-term mechanisms by which SSRIs produce their effects. This means Semax’s interaction with the serotonin system may actually run more parallel to — and complementary with — SSRI mechanisms rather than against them.
The dopaminergic effects of Semax are largely independent of SSRI pathways, which is where most of its stimulating and focus-related research properties originate.
The Realistic Picture
There is no published clinical research specifically examining Semax + SSRI or Selank + SSRI combinations in humans. That’s the honest starting point. What exists is mechanistic inference — an understanding of what each compound does individually, and where those pathways logically intersect.
Based on that:
Selank + SSRI carries more theoretical serotonergic overlap, primarily due to Selank’s influence on serotonin degradation. The risk isn’t equivalent to combining two direct serotonergic drugs, but it’s not zero either — and anyone on an SSRI should not be adding Selank to any research protocol without their physician’s awareness.
Semax + SSRI is a lower-concern combination from a serotonin standpoint. The BDNF pathway Semax primarily acts through has been studied in the context of supporting antidepressant efficacy, not competing with it. The dopaminergic activity is largely orthogonal to SSRI mechanisms.
In both cases — physician involvement isn’t optional. These are research peptides with no human clinical trial data on SSRI co-administration. Only a physician with full knowledge of the medication picture can make a responsible call.
General Precaution
Semax is the lower-overlap option. Its core mechanisms — BDNF upregulation, dopaminergic modulation, neuroprotection — run largely parallel to SSRI pathways rather than through them.
Selank is the higher-overlap option, specifically because of its serotonin degradation mechanism. That doesn’t make it dangerous by default, but it makes physician consultation more important before any research involving the combination.
SSRIs are not supplements. They’re prescription medications managing a neurological condition, and adding anything that touches the serotonin system without the prescribing physician’s knowledge is not a risk worth taking.
More SSRI + nootropic peptide breakdowns coming. If there’s a specific compound you want covered next, drop it in the comments.
— Derek
All content is for educational and research purposes only. Research subjects in all discussed contexts are non-human. Nothing here constitutes medical advice or a recommendation to change, add, or discontinue any medication or treatment protocol.

Unsubscribe https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXNraS5zdWJzdGFjay5jb20vYWN0aW9uL2Rpc2FibGVfZW1haWw_dG9rZW49ZXlKMWMyVnlYMmxrSWpveU56TTJNakl6T1Rnc0luQnZjM1JmYVdRaU9qRTVNVGc0TmpBeE5Td2lhV0YwSWpveE56YzBNamcwTmpNeExDSmxlSEFpT2pFNE1EVTRNakEyTXpFc0ltbHpjeUk2SW5CMVlpMHpNelkxTXpZM0lpd2ljM1ZpSWpvaVpHbHpZV0pzWlY5bGJXRnBiQ0o5LnlrNHkxQ3k0WGNaRkFIamFaQWcwaVJ2U1hfQ1BvV2YtMzZham9nOFV4UDQiLCJwIjoxOTE4ODYwMTUsInMiOjMzNjUzNjcsImYiOnRydWUsInUiOjI3MzYyMjM5OCwiaWF0IjoxNzc0Mjg0NjMxLCJleHAiOjIwODk4NjA2MzEsImlzcyI6InB1Yi0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ9.0Sul4jTQyggOgd-2b2xXXA88wdcxOB-CGoj4pjik-w0?